You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


CMA fines Advanz over ‘excessive and unfair’ pricing of thyroid drug

The Competition and Markets Authority (CMA) in the UK has found that pharma company Advanz charged ‘excessive and unfair’ prices for supplying liothyronine tablets, a common medication used to treat thyroid hormone deficiency.